Clinical Trial Update: Intravitreal Ranibizumab 0.5MG, or 1.0mg for RVO With Macular Edema Previously Receiving Bevacizumab [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial evaluating intravitreal ranibizumab (0.5 mg or 1.0 mg) for macular edema due to branch or central retinal vein occlusion in patients previousl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Branch Retinal Vein Occlusion
• Central Retinal Vein Occlusion
• Macular Edema

Drugs mentioned

• Lucentis (ranibizumab)

Snippet

Sponsor: Hanscom, Thomas, M.D. | Conditions: Branch Retinal Vein Occlusion, Central Retinal Vein Occlusion | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2015-04-29